We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+1.36%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$895M
AUM Growth
+$57.1M
Cap. Flow
+$128M
Cap. Flow %
14.27%
Top 10 Hldgs %
69.58%
Holding
37
New
4
Increased
8
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$82.5M
2
NTRA icon
Natera
NTRA
+$57.7M
3
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$20.6M
4
SLDB icon
Solid Biosciences
SLDB
+$17.1M
5
XFOR icon
X4 Pharmaceuticals
XFOR
+$9.18M

Top Sells

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$28.8M
2
THRD
Third Harmonic Bio
THRD
+$18.9M
3
DVAX
Dynavax Technologies
DVAX
+$17.4M
4
ARYE
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
+$4.91M
5
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
+$4.88M

Sector Composition

Rank Sector Weight
1 Healthcare 99.35%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$126M 14.04%
4,831,307
– –
NUVL
2
DELISTED
Nuvalent
NUVL
$107M 11.9%
3,577,267
+149,253
+4% +$4.16M
NAMS icon
3
NewAmsterdam Pharma
NAMS
$3.35B
$90.5M 10.11%
+8,300,000
New +$82.5M
NTRA icon
4
Natera
NTRA
$45.3B
$56.2M 6.28%
+1,400,000
New +$57.7M
MRSN
5
DELISTED
Mersana Therapeutics
MRSN
$50.8M 5.67%
346,547
– –
ARQT icon
6
Arcutis Biotherapeutics
ARQT
$3.24B
$44.4M 4.96%
3,000,000
– –
CRNX icon
7
Crinetics Pharmaceuticals
CRNX
$8.94B
$42.2M 4.72%
2,305,558
– –
DVAX
8
DELISTED
Dynavax Technologies
DVAX
$41.7M 4.66%
3,915,000
-1,500,000
-28% -$17.4M
PHVS icon
9
Pharvaris
PHVS
$2.42B
$35.8M 4%
3,180,601
– –
TVRD
10
Tvardi Therapeutics
TVRD
$22M
$29M 3.24%
74,890
+1,349
+2% +$512K
PTGX icon
11
Protagonist Therapeutics
PTGX
$9.62B
$25.8M 2.88%
2,364,410
+103,838
+5% +$876K
ANNX icon
12
Annexon
ANNX
$893M
$25.3M 2.82%
4,886,616
+1,284,690
+36% +$7.06M
EQRX
13
DELISTED
EQRx, Inc. Common Stock
EQRX
$24.6M 2.75%
10,003,573
– –
CTIC
14
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$22.7M 2.54%
+3,777,308
New +$20.6M
NRIX icon
15
Nurix Therapeutics
NRIX
$2.67B
$20M 2.24%
1,822,883
– –
SVRA icon
16
Savara
SVRA
$1.18B
$18M 2.01%
11,622,598
– –
SLDB icon
17
Solid Biosciences
SLDB
$912M
$16.8M 1.88%
3,130,422
+2,601,761
+492% +$17.1M
TNGX icon
18
Tango Therapeutics
TNGX
$4.47B
$13.9M 1.56%
1,921,790
– –
TSVT
19
DELISTED
2seventy bio
TSVT
$13.2M 1.48%
1,408,901
– –
XFOR icon
20
X4 Pharmaceuticals
XFOR
$439M
$12.1M 1.35%
406,750
+193,769
+91% +$9.18M
AVIR icon
21
Atea Pharmaceuticals
AVIR
$407M
$12M 1.34%
2,485,638
– –
ACAD icon
22
Acadia Pharmaceuticals
ACAD
$5.08B
$11.2M 1.25%
701,402
+90,879
+15% +$1.42M
CCCC icon
23
C4 Therapeutics
CCCC
$407M
$9.69M 1.08%
1,642,210
– –
RPID icon
24
Rapid Micro Biosystems
RPID
$87.2M
$9.53M 1.07%
8,434,560
– –
SYRS
25
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$7.63M 0.85%
2,124,694
+1,042,290
+96% +$4.52M
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q4 2022 Portfolio in Review

As of Q4 2022, Bain Capital Life Sciences Investors held 37 positions worth $895M, up 6.8% from $838M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Bain Capital Life Sciences Investors deployed $128M of net new capital in Q4 2022, opening 4 new positions and adding to 8 existing holdings. Its largest new stake was NewAmsterdam Pharma: 8,300,000 shares worth $90.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Third Harmonic Bio, an estimated $18.9M trimmed.

  • Bain Capital Life Sciences Investors's largest Q4 2022 buy was NewAmsterdam Pharma: 8,300,000 shares worth $90.5M.
  • Bain Capital Life Sciences Investors added most to Solid Biosciences in Q4 2022, an estimated $17.1M increase.
  • Bain Capital Life Sciences Investors's biggest Q4 2022 reduction was Third Harmonic Bio, cutting an estimated $18.9M.
  • Bain Capital Life Sciences Investors fully exited Amylyx Pharmaceuticals in Q4 2022, selling an estimated $28.8M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 70% of its $895M portfolio in Q4 2022.
  • Bain Capital Life Sciences Investors opened 4 new positions and closed 4 in Q4 2022.
  • Bain Capital Life Sciences Investors's portfolio value rose 6.8% quarter-over-quarter to $895M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2022, filed 14 Feb 2023.